Parminder Singh, MD, presented “Point: Bladder Sparing Approach for Muscle Invasive Bladder Cancer” during the 31st Annual Perspectives in Urology: Point-Counterpoint, on October 18, 2024, in Scottsdale, Arizona.
How to cite: Singh, Parminder. “Point: Bladder Sparing Approach for Muscle Invasive Bladder Cancer.” October 18, 2024. Accessed Feb 2025. https://grandroundsinurology.com/point-bladder-sparing-approach-for-muscle-invasive-bladder-cancer/
Point: Bladder Sparing Approach for Muscle Invasive Bladder Cancer – Summary
Parminder Singh, MD, examines bladder preservation strategies for muscle-invasive bladder cancer (MIBC). In this 10-minute presentation, Dr. Singh emphasizes the importance of patient-centered approaches. The discussion highlights data from a Johns Hopkins survey indicating that patients prioritize bladder retention alongside cancer control, showing a willingness to tolerate moderate toxicity for this outcome.
Dr. Singh reviews pivotal studies, including SWOG 87-10 and the NIAGARA trial, demonstrating improvements in survival with neoadjuvant therapies, particularly when incorporating immunotherapy. He contrasts the high complication rates associated with radical cystectomy with the favorable survival and bladder preservation outcomes achieved through trimodality therapy in carefully selected patients.
Dr. Singh discusses advances in patient stratification using biomarkers like ctDNA and improved imaging modalities such as MRI, which enhance the selection of candidates for bladder preservation. His presentation underscores the need for individualized treatment decisions based on tumor characteristics, patient preferences, and emerging evidence, providing a comprehensive update on bladder cancer management.
About the 31st Annual Perspectives in Urology: Point Counterpoint conference: Presented by Program Chair and Grand Rounds in Urology Editor-in-Chief E. David Crawford, MD, this conference brought together leading experts in urology, medical oncology, and radiation oncology to discuss and debate the latest topics in genitourinary cancers, primarily prostate cancer and bladder cancer. This interactive conference offered topical lectures, pro/con debates, interesting-case presentations, interactive panel discussions, and interactive audience and faculty networking.
ABOUT THE AUTHOR
Dr. Parminder Singh, MD, is an Assistant Professor of Hematology and Oncology at Mayo Clinic in Phoenix, Arizona, and a Genitourinary oncologist who specializes in bladder cancer with research focus in developing novel therapeutics. He is the Study Chair on SWOG 1806, which is a phase III clinical trial evaluating trimodality therapy in combination with atezolizumab in muscle-invasive bladder cancer.
